Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc > Bud/Offer

<< Previous

Bullboard Posts

Next >>

Comment by Budamanon Oct 13, 2021 10:09am

249 Views

Post# 34000649

RE:Bud/Offer

It is pure SP manipulation on extremely low volume. It demonstrates how closely people are clutching their shares. They should be at about 85 percent data recovery at this time. Once we hit 90 percent, I expect the SP to start climbing back towards $0.70/share. In my opinion only. Thanks-Buda.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China